peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Annual Report 2008 (In Swedish)

5 Apr 2009, 08:00
Regulatory information
The annual report for Hansa Medical 2008 (In Swedish) is available as PDF the 15th of April 2009 through A print version of the annual report can be ordered through

Lund, April 15, 2009Hansa Medical AB (publ)For more information, please contact:Emanuel Björne, CEOMobile: +46 (0)70 717 54 77E-mail: emanuel.bjorne@hansamedical.comHansa Medical is a preclinical and early clinical biopharmaceutical development company focused on inflammation. The company develops three primary products, IdeS, anti-alpha-11 and HMD-301. IdeS is a novel treatment prior to organ transplantation. Anti-alpha-11 is a novel and more specific rheumatoid arthritis treatment. HMD-301 is a novel diagnostic method for diagnosis and prognosis of severe sepsis. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED.